Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018, Article ID 4826973, 7 pages
https://doi.org/10.1155/2018/4826973
Research Article

Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn’s Disease

1Department of Internal Medicine, Kyung Hee University Hospital at Gang Dong, Kyung Hee University College of Medicine, Seoul, Republic of Korea
2Department of Internal Medicine, Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea
3Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Kyung-Jo Kim; moc.liamg@sodneluspac

Received 21 February 2017; Accepted 3 May 2017; Published 18 January 2018

Academic Editor: Stephen Fink

Copyright © 2018 Min Seob Kwak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Cosnes, S. Cattan, A. Blain et al., “Long-term evolution of disease behavior of Crohn’s disease,” Inflammatory Bowel Diseases, vol. 8, no. 4, pp. 244–250, 2002. View at Publisher · View at Google Scholar
  2. S. H. Park, S. K. Yang, S. K. Park et al., “Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea,” Inflammatory Bowel Diseases, vol. 20, no. 3, pp. 488–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. B. Hanauer and W. Sandborn, “Management of Crohn’s disease in adults,” The American Journal of Gastroenterology, vol. 96, no. 3, pp. 635–643, 2001. View at Google Scholar
  4. A. V. Ramadas, S. Gunesh, G. A. O. Thomas, G. T. Williams, and A. B. Hawthorne, “Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates,” Gut, vol. 59, no. 9, pp. 1200–1206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. L. Lakatos, P. A. Golovics, G. David et al., “Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977–2009,” The American Journal of Gastroenterology, vol. 107, no. 4, pp. 579–588, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Sandborn, B. G. Feagan, and G. R. Lichtenstein, “Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 7, pp. 987–1003, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Esrailian, B. M. R. Spiegel, L. E. Targownik, M. C. Dubinsky, S. R. Targan, and I. M. Gralnek, “Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 7, pp. 1005–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. B. Gearry, Y. Ajlouni, S. Nandurkar, J. H. Iser, and P. R. Gibson, “5-Aminosalicylic acid (mesalazine) use in Crohn’s disease: a survey of the opinions and practice of Australian gastroenterologists,” Inflammatory Bowel Diseases, vol. 13, no. 8, pp. 1009–1015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Mantzaris, M. Sfakianakis, E. Archavlis et al., “A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis,” The American Journal of Gastroenterology, vol. 99, no. 6, pp. 1122–1128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Campbell and S. Ghosh, “Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy,” European Journal of Gastroenterology & Hepatology, vol. 13, no. 11, pp. 1297–1301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Lennard-Jones, “Classification of inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 170, pp. 2–6, 1989. View at Publisher · View at Google Scholar · View at Scopus
  12. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” Canadian Journal of Gastroenterology, vol. 19, Supplement A, pp. 5a–36a, 2005. View at Publisher · View at Google Scholar
  13. S.-K. Park, S.-K. Yang, B. D. Ye et al., “The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis,” Scandinavian Journal of Gastroenterology, vol. 48, no. 12, pp. 1386–1393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman, “A controlled double blind study of azathioprine in the management of Crohn’s disease,” Gut, vol. 37, no. 5, pp. 674–678, 1995. View at Publisher · View at Google Scholar
  15. D. H. Present, B. I. Korelitz, N. Wisch, J. L. Glass, D. B. Sachar, and B. S. Pasternack, “Treatment of Crohn’s disease with 6-mercaptopurine — a long-term, randomized, double-blind study,” The New England Journal of Medicine, vol. 302, no. 18, pp. 981–987, 1980. View at Publisher · View at Google Scholar
  16. E. Prefontaine, L. R. Sutherland, J. K. Macdonald, and M. Cepoiu, “Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease,” Cochrane Database of Systematic Reviews, no. 1, article Cd000067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Prefontaine, J. K. Macdonald, and L. R. Sutherland, “Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease,” Cochrane Database of Systematic Reviews, no. 6, article Cd000545, 2010. View at Publisher · View at Google Scholar
  18. M. A. Smith, P. Blaker, A. M. Marinaki, S. H. Anderson, P. M. Irving, and J. D. Sanderson, “Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol,” Journal of Crohn's and Colitis, vol. 6, no. 9, pp. 905–912, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. L. Szumlanski and R. M. Weinshilboum, “Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine,” British Journal of Clinical Pharmacology, vol. 39, no. 4, pp. 456–459, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. L. D. Lewis, A. Benin, C. L. Szumlanski et al., “Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction,” Clinical Pharmacology & Therapeutics, vol. 62, no. 4, pp. 464–475, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Lowry, C. Szumlanski, R. Weinshilboum, and W. Sandborn, “Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction,” Gastroenterology, vol. 116, no. 6, pp. 1505-1506, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Andrews, S. P. L. Travis, P. R. Gibson, and C. Gasche, “Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?” Alimentary Pharmacology and Therapeutics, vol. 29, no. 5, pp. 459–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Beaugerie, P. Seksik, I. Nion–Larmurier, J.-P. Gendre, and J. Cosnes, “Predictors of Crohn’s disease,” Gastroenterology, vol. 130, no. 3, pp. 650–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Yarur, S. G. Strobel, A. R. Deshpande, and M. T. Abreu, “Predictors of aggressive inflammatory bowel disease,” Gastroenterology & Hepatology, vol. 7, no. 10, pp. 652–659, 2011. View at Google Scholar
  25. X. Treton, Y. Bouhnik, J. Y. Mary et al., “Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse,” Clinical Gastroenterology and Hepatology, vol. 7, no. 1, pp. 80–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Rayner, A. L. Hart, C. M. M. Hayward, A. V. Emmanuel, and M. A. Kamm, “Azathioprine dose escalation in inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 1, pp. 65–71, 2004. View at Publisher · View at Google Scholar · View at Scopus